Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1975 2
1976 6
1978 1
1980 1
1981 3
1982 1
1983 4
1984 1
1985 3
1986 2
1987 4
1988 7
1989 4
1990 3
1991 7
1992 12
1993 7
1994 8
1995 6
1996 7
1997 5
1998 7
1999 10
2000 8
2001 12
2002 16
2003 16
2004 19
2005 14
2006 16
2007 12
2008 19
2009 21
2010 26
2011 31
2012 35
2013 29
2014 33
2015 48
2016 36
2017 28
2018 34
2019 44
2020 55
2021 62
2022 49
2023 52
2024 24

Text availability

Article attribute

Article type

Publication date

Search Results

759 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Did you mean m j whelan (248 results)?
Colchicine in Patients with Chronic Coronary Disease.
Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, The SHK, Xu XF, Ireland MA, Lenderink T, Latchem D, Hoogslag P, Jerzewski A, Nierop P, Whelan A, Hendriks R, Swart H, Schaap J, Kuijper AFM, van Hessen MWJ, Saklani P, Tan I, Thompson AG, Morton A, Judkins C, Bax WA, Dirksen M, Alings M, Hankey GJ, Budgeon CA, Tijssen JGP, Cornel JH, Thompson PL; LoDoCo2 Trial Investigators. Nidorf SM, et al. N Engl J Med. 2020 Nov 5;383(19):1838-1847. doi: 10.1056/NEJMoa2021372. Epub 2020 Aug 31. N Engl J Med. 2020. PMID: 32865380 Clinical Trial.
A primary end-point event occurred in 187 patients (6.8%) in the colchicine group and in 264 patients (9.6%) in the placebo group (incidence, 2.5 vs. 3.6 events per 100 person-years; hazard ratio, 0.69; 95% confidence interval [CI], 0.57 to 0.83; P<0.001). A key seconda …
A primary end-point event occurred in 187 patients (6.8%) in the colchicine group and in 264 patients (9.6%) in the placebo group (incidence …
A new staging system for cardiac transthyretin amyloidosis.
Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, Quarta CC, Rezk T, Whelan CJ, Gonzalez-Lopez E, Lane T, Gilbertson JA, Rowczenio D, Petrie A, Hawkins PN. Gillmore JD, et al. Eur Heart J. 2018 Aug 7;39(30):2799-2806. doi: 10.1093/eurheartj/ehx589. Eur Heart J. 2018. PMID: 29048471

Median survival among 393 (45%) Stage I patients was 69.2 months, 334 (38%) Stage II patients was 46.7 months, and 142 (16%) Stage III patients was 24.1 months (P < 0.0001). After adjusting for age, compared with Stage I, the hazard ratio (HR) for death for Stage II was

Median survival among 393 (45%) Stage I patients was 69.2 months, 334 (38%) Stage II patients was 46.7 months, and 142 (16%) Stage III patie …
Regional Nodal Irradiation in Early-Stage Breast Cancer.
Whelan TJ, Olivotto IA, Parulekar WR, Ackerman I, Chua BH, Nabid A, Vallis KA, White JR, Rousseau P, Fortin A, Pierce LJ, Manchul L, Chafe S, Nolan MC, Craighead P, Bowen J, McCready DR, Pritchard KI, Gelmon K, Murray Y, Chapman JA, Chen BE, Levine MN; MA.20 Study Investigators. Whelan TJ, et al. N Engl J Med. 2015 Jul 23;373(4):307-16. doi: 10.1056/NEJMoa1415340. N Engl J Med. 2015. PMID: 26200977 Free PMC article. Clinical Trial.
At the 10-year follow-up, there was no significant between-group difference in survival, with a rate of 82.8% in the nodal-irradiation group and 81.8% in the control group (hazard ratio, 0.91; 95% confidence interval [CI], 0.72 to 1.13; P=0.38). The rates of disease-free s …
At the 10-year follow-up, there was no significant between-group difference in survival, with a rate of 82.8% in the nodal-irradiation group …
Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis.
Lane T, Fontana M, Martinez-Naharro A, Quarta CC, Whelan CJ, Petrie A, Rowczenio DM, Gilbertson JA, Hutt DF, Rezk T, Strehina SG, Caringal-Galima J, Manwani R, Sharpley FA, Wechalekar AD, Lachmann HJ, Mahmood S, Sachchithanantham S, Drage EPS, Jenner HD, McDonald R, Bertolli O, Calleja A, Hawkins PN, Gillmore JD. Lane T, et al. Circulation. 2019 Jul 2;140(1):16-26. doi: 10.1161/CIRCULATIONAHA.118.038169. Epub 2019 May 21. Circulation. 2019. PMID: 31109193
Patients with V122I-hATTR-CM were more impaired functionally ( P<0.001) and had worse measures of cardiac disease ( P<0.001) at the time of diagnosis, a greater decline in quality of life, and poorer survival ( P<0.001) in comparison with the other s …
Patients with V122I-hATTR-CM were more impaired functionally ( P<0.001) and had worse measures of cardiac disease ( P<0. …
Dietary fiber intervention on gut microbiota composition in healthy adults: a systematic review and meta-analysis.
So D, Whelan K, Rossi M, Morrison M, Holtmann G, Kelly JT, Shanahan ER, Staudacher HM, Campbell KL. So D, et al. Am J Clin Nutr. 2018 Jun 1;107(6):965-983. doi: 10.1093/ajcn/nqy041. Am J Clin Nutr. 2018. PMID: 29757343 Free article.

(standardized mean difference (SMD): 0.64; 95% CI: 0.42, 0.86; P < 0.00001) and Lactobacillus spp. (SMD: 0.22; 0.03, 0.41; P = 0.02) as well as fecal butyrate concentration (SMD: 0.24; 0.00, 0.47; P = 0.05) compared with placebo/low-fiber comparators. Subg

(standardized mean difference (SMD): 0.64; 95% CI: 0.42, 0.86; P < 0.00001) and Lactobacillus spp. (SMD: 0.22; 0.03, 0.41; P

Nutrient Intake, Diet Quality, and Diet Diversity in Irritable Bowel Syndrome and the Impact of the Low FODMAP Diet.
Staudacher HM, Ralph FSE, Irving PM, Whelan K, Lomer MCE. Staudacher HM, et al. J Acad Nutr Diet. 2020 Apr;120(4):535-547. doi: 10.1016/j.jand.2019.01.017. Epub 2019 Apr 24. J Acad Nutr Diet. 2020. PMID: 31029650 Clinical Trial.
However, there was lower intake of starch (109 g/day) vs habitual control diet (128 g/day; P=0.030), and higher intake of vitamin B-12 (6.1 mug/day) vs habitual (3.9 mug/day) and sham control diets (4.7 mug/day; P<0.01). Overall scores for diet quality were lower …
However, there was lower intake of starch (109 g/day) vs habitual control diet (128 g/day; P=0.030), and higher intake of vitamin B-1 …
Physiotherapy as an Initial Treatment Option for Femoroacetabular Impingement: A Systematic Review of the Literature and Meta-analysis of 5 Randomized Controlled Trials.
Hoit G, Whelan DB, Dwyer T, Ajrawat P, Chahal J. Hoit G, et al. Am J Sports Med. 2020 Jul;48(8):2042-2050. doi: 10.1177/0363546519882668. Epub 2019 Nov 27. Am J Sports Med. 2020. PMID: 31774704

Pooled analysis across all studies demonstrated improved outcomes in the treatment groups compared with the controls (standardized mean difference [SMD], 0.76; 95% CI, 0.38-1.13; P < .0001). Core strengthening (SMD, 0.82; 95% CI, 0.39-1.26; P = .0002), active phy

Pooled analysis across all studies demonstrated improved outcomes in the treatment groups compared with the controls (standardized mean diff …
Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials.
Taylor C, Correa C, Duane FK, Aznar MC, Anderson SJ, Bergh J, Dodwell D, Ewertz M, Gray R, Jagsi R, Pierce L, Pritchard KI, Swain S, Wang Z, Wang Y, Whelan T, Peto R, McGale P; Early Breast Cancer Trialists’ Collaborative Group. Taylor C, et al. J Clin Oncol. 2017 May 20;35(15):1641-1649. doi: 10.1200/JCO.2016.72.0722. Epub 2017 Mar 20. J Clin Oncol. 2017. PMID: 28319436 Free PMC article.

Meta-analyses yielded lung cancer incidence 10 years after radiotherapy RR of 2.10 (95% CI, 1.48 to 2.98; P < .001) on the basis of 134 cancers, indicating 0.11 (95% CI, 0.05 to 0.20) ERR per Gy whole-lung dose. For cardiac mortality, RR was 1.30 (95% CI, 1.15 to 1.46;

Meta-analyses yielded lung cancer incidence 10 years after radiotherapy RR of 2.10 (95% CI, 1.48 to 2.98; P < .001) on the basis o

Salivary Detection of COVID-19.
Caulley L, Corsten M, Eapen L, Whelan J, Angel JB, Antonation K, Bastien N, Poliquin G, Johnson-Obaseki S. Caulley L, et al. Ann Intern Med. 2021 Jan;174(1):131-133. doi: 10.7326/M20-4738. Epub 2020 Aug 28. Ann Intern Med. 2021. PMID: 32857591 Free PMC article. No abstract available.
Developing vaccines against epidemic-prone emerging infectious diseases.
Bernasconi V, Kristiansen PA, Whelan M, Román RG, Bettis A, Yimer SA, Gurry C, Andersen SR, Yeskey D, Mandi H, Kumar A, Holst J, Clark C, Cramer JP, Røttingen JA, Hatchett R, Saville M, Norheim G. Bernasconi V, et al. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020 Jan;63(1):65-73. doi: 10.1007/s00103-019-03061-2. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020. PMID: 31776599 Free PMC article. Review.
759 results